ClinicalTrials.gg
RecruitingNCT07848165Updated Sep 29, 2026

Probiotic Role in Prevention of Ventilator Associated Pneumonia in Critically- Ill Children Admitted at Pediatric Intensive Care Unit

An interventional study of Probiotics and Standard management in Probiotic, Ventilator Associated Pneumonia and Critically- Ill Children, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Pneumonia, Ventilator-Associated with a site in Egypt — 8 open to participants now, 8 under way, none of them phase 3. Pneumonia, Ventilator-Associated · Egypt.

Planned enrollment
18th of 22
68 · median 100
Started
2026
with 4 others
No phase
16 of 28
6 open now
Registered
26th of 28
by date
Lead sponsor
3 of 28
Tanta University

Among the 28 studies in Pneumonia, Ventilator-Associated with a site in Egypt, this one is the 18th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2026, is one of 16 with no phase, and was the 26th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

8 of the 28 studies in Pneumonia, Ventilator-Associated with a site in Egypt are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pneumonia, Ventilator-Associated with a site in Egypt, or all of them as a file.
02

Study summary

The aim of the work is to evaluate the impact of Probiotics supplementation on prevention of ventilator associated pneumonia in critically ill children admitted at Pediatric Intensive Care Unit at Tanta University Hospitals.

Read the detailed description

Critically ill children are the children whom requiring, or potentially requiring, high reliance or serious consideration whether in medical, surgical or trauma-related fields.

Based on the time of onset of Ventilator Associated Pneumonia (VAP), it can be divided into two types. Early-onset VAP occurs during the first four days of mechanical ventilation and is usually caused by antibiotic sensitive bacteria. Late-onset VAP develops five or more days after initiation of MV and is caused by multidrug-resistant (MDR) pathogens .VAP is associated with a high rate of all-cause mortality and a prolonged duration of mechanical ventilation and intensive care unit stay.

03

Conditions studied

  • Probiotic
  • Ventilator Associated Pneumonia
  • Critically- Ill Children
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Critically ill children from 1 month to 18 years.
  • Both sexes.
  • Ventilated not due to chest infection.

Exclusion criteria

Exclusion Criteria:

  • Children recently received enteral vaccines.
  • Children receiving chronic such as chemotherapy agents. and immunosuppressive medications, and high dose (more than 1 milligram per kilogram).
  • Children with of enteral feeding.
  • Children with gastrointestinal bleeding.
  • Children with open wounds following major surgery.
  • Children with short gut syndrome.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Group I

    Critically ill ventilated children will receive standard management plus probiotics.

    Drug: Probiotics

  • Active comparator
    Group II

    Critically ill ventilated children will receive standard management only.

    Other: Standard management

Interventions

  • DrugProbiotics

    Critically ill ventilated children will receive standard management plus probiotics.

  • OtherStandard management

    Critically ill ventilated children will receive standard management only.

06

What researchers measure

Primary outcomes

  1. Incidence of ventilator-associated pneumonia

    Incidence of ventilator-associated pneumonia (VAP) diagnosed according to predefined CDC/NHSN pediatric criteria

    Time frame: During the first 28 days after initiation of mechanical ventilation

Secondary outcomes

  1. Duration of mechanical ventilation

    Duration of invasive mechanical ventilation will be measured in days from initiation of mechanical ventilation until successful extubation.

    Time frame: Up to 28 days

  2. Pediatric intensive care unit length of stay

    Pediatric intensive care unit (PICU) length of stay will be measured in days from PICU admission until PICU discharge.

    Time frame: Up to 28 days

  3. Incidence of mortality

    Incidence of mortality will be recorded.

    Time frame: Up to 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.

Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 7 months is below that.

Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2026
First posted
Sep 29, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848165
Lead sponsor
Tanta University
Responsible party
Yomna Gaber El-Feky (Lecturer of Pediatrics, Faculty of Medicine, Tanta University, Egypt., Tanta University) — Principal investigator
First posted
Sep 29, 2026
Start date
Jul 1, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Yomna G El-Feky, MD
Contact
Youmna.elfeky@med.tanta.edu.eg
00201005562005

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion